Genomic Medicines

End-to-end Solutions to Enable Genomic Medicines

Precision NanoSystems provides a full stack of technologies and solutions with leading experience to accelerate the design, development and manufacturing of promising Genomic Medicines.

  • Disease Target-8
    Disease Target
    Biology insights can identify target gene(s) driving disease
Genomic Medicine Toolkit
  • circle_payload
    Genomic Payload Platform
    Choose RNA/DNA to silence, express, or edit target gene(s)
  • LNP icon-01
    GenVoy™ Delivery Platform
    Lipid nanoparticles (LNPs) protect & deliver RNA/DNA to target cells
  • circle_manufacturing
    NanoAssemblr® Manufacturing Platform
    Microfluidics manufactures genomic medicines seamlessly from discovery to clinic
  • Updated_Scientists_Icon
    Drug Development Expertise
    Leverage world-leading expertise in genomic medicine development
Genomic medicines are revolutionizing how diseases are treated by addressing dysfunctional genes and gene networks responsible for a wide range of diseases. Genomic medicines come in several forms that can modulate gene expression or edit genes.

Silence Genes

Silence Genes

siRNA and other non-coding RNA

Express Genes

Express Genes mRNA

Messenger RNA

Express Genes

Express Genes DNA


Edit Genes

Edit Genes CRISPR

CRISPR and other gene editing tools


Learn More

Get Started
To learn how Precision NanoSystems can help accelerate the design, development and manufacturing of your Genomic Medicines, contact a Scientific Specialist.
How to Develop a Genomic Medicine


Precision NanoSystems Framework provides a roadmap for genomic medicine development. The specific Workflows for development of vaccines, gene therapy and cell therapy are designed to accelerate genomic medicine development by using the Framework together with components of the Genomic Medicine Toolkit to increase effectiveness and efficiency across the drug development process.



Precision NanoSystems Genomic Medicine Development Framework


Validate molecular target(s) in vitro/vivo


Screen sequence, base modifications and excipient library

Systematically test process and formulation parameters to physico-chemical properties and in vivo biological activity


Down-select lead formulations and optimize key process parameters

Additional animal studies in second species to assess efficacy and toxicity


Process and formulation parameters & analytical methods to ensure product quality and performance are developed and finalized

GMP equipment, manufacturing process, analytical methods and QMS transferred into Clean Room Facility and validated with engineering run.


Investigational New Drug (IND) application submitted


GMP batch production of Nanomedicine for clinical testing - Phase 1, 2 & 3

Instrument, process and analytical methods transferred to commercial production site


New Drug Application (NDA) submitted


Commercial production of Nanomedicine initiated

Woman receiving shot
mRNA & DNA-based vaccines Prophylactic & therapeutic
Infectious Disease & Oncology
Population-based to individualized
Baby sleeping
Silence, express, or edit genes
Focus on rare disease
Population-based to individualized
Man in hospital bed
Immune cells including T-Cells
Focus on oncology
Autologous & allogeneic


Precision NanoSystems' learning platform for topics, techniques and technologies to help accelerate non-viral genomic medicine development.

Get Started